

DISCLAIMER

This presentation contains forward-looking statements that reflect the current views of management, and which are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this presentation. Statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann's control. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann is providing the information in this presentation as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise. This presentation constitutes neither an offer to sell nor a solicitation to buy any securities.

straumanngroup


AGENDA


Highlights	Guillaume Daniellot	
Financials	Yang Xu	
Recent achievements & strategy	Guillaume Daniellot	
Outlook 2024	Guillaume Daniellot	
Q&A and upcoming events	Guillaume Daniellot, Yang Xu	


straumanngroup



SOLID START INTO 2024 Revenue in CHF Regional performance Organic revenue growth1 644m China 15.1% dynamic demand in most of our business or 8.1% in CHF exceptional organic growth boosted by continued strong momentum and low segments comparison base Implantology Orthodontics Outlook 2024² confirmed High single-digit **ClearPilot 8.0 iExcel** organic revenue growth high-performance premium implant system ClearCorrect further improved its value profitability at around 26% at constant 2023 launched in North America proposition currency rates, or between 24% and 25% including expected FX headwind straumanngroup 5 1 Organic growth excluding FX and M&A effects 2 Barring unforeseen events










GOOD MOMENTUM CONTINUED ACROSS ALL B2B BUSINESSES Tooth replacement and restoration Tooth alignment Digital solutions straumanngroup









CHALLENGER BRANDS CONTINUED TO EXPAND GLOBALLY

NAM

EMEA

O NEODENT

O NEODE



IMPROVED CUSTOMER EXPERIENCE WITH DIGITAL WORKFLOW
STRAUMANN AXS RECEIVED ISO 27001 CERTIFICATION, AN IMPORTANT STEP IN CYBERSECURITY

ISO 27001

| Gentle |

FURTHER INVESTMENTS IN ORTHODONTICS B2B BUSINESS

Technology



ClearPilot 8.0

Service



Center in Costa Rica

Commercialization



Ortho Sales Academy

straumanngroup

17

ONGOING INVESTMENTS IN GROWTH

Capacity expansion



Technology



Digital customer platform

People



EDGE!UP

straumanngroup



2024 OUTLOOK CONFIRMED

BARRING UNFORESEEN CIRCUMSTANCES

Market environment and assumption

- Uncertain economic environment remains
- Group believes global patient flow should remain stable
- Outgrowing market vs. prior year

Revenue and profitability

- Organic revenue growth in the high single-digit percentage range
- Profitability at around 26% at constant 2023 currency rates or between 24% and 25% including expected FX headwind

straumanngroup



CALENDAR OF UPCOMING INVESTOR EVENTS

2024	Event	Location
15 May	Deutsche Bank Q1 Roadshow	Frankfurt
16 May	Mirabaud Swiss Equity Conference	Geneva
5 June	BNP Paribas Exane Conference	Paris
11 June	Stifel Swiss Equities Conference	Interlaken
20 June	JP Morgan European HC Conference	London
27 June	Stifel European HC Conference	Lyon
14 August	Q2 Earnings Announcement	Basel
15-16 August	Jefferies Q2 Roadshow	London

straumanngroup